Antidepressant Effects of Nitrous Oxide

Description

To evaluate the acute and sustained antidepressant effects of nitrous oxide in people with major depressive disorder; and further evaluate these effects by identifying the optimal dose and regimen to guide current practice, and to plan a future large pragmatic trial.

Conditions

Major Depressive Disorder, Treatment Resistant Depression

Talk to us

Study Overview

On this page

Study Details

Study overview

To evaluate the acute and sustained antidepressant effects of nitrous oxide in people with major depressive disorder; and further evaluate these effects by identifying the optimal dose and regimen to guide current practice, and to plan a future large pragmatic trial.

Evaluation of the Antidepressant Effects of Nitrous Oxide in People With Major Depressive Disorder

Antidepressant Effects of Nitrous Oxide

Condition
Major Depressive Disorder
Intervention / Treatment

-

Contacts and Locations

Chicago

University of Chicago Medicine, Chicago, Illinois, United States, 60637

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Adult (≥18 years, both sexes)
  • 2. DSM-5 criteria for MDD without psychosis, as determined using a structured clinical interview \[Mini International Neuropsychiatric Interview\], MDD, defined by a pre-treatment score \>16 on the HDRS-21 scale and meeting DSM-5 for MDD
  • 1. A current or past history of bipolar disorder, schizophrenia, or schizoaffective disorder.
  • 2. Current obsessive-compulsive disorder, panic disorder, or documented Axis II diagnoses
  • 3. Active suicidal intention, as determined by clinical interview assessment tool (Sheehan-STS) and clinical examination
  • 4. Active or recent (\<12 months) substance use disorder; excluding nicotine
  • 5. Administration of NMDA-antagonists (e.g., ketamine) in previous 3 months
  • 6. Ongoing treatment with ECT
  • 7. Presence of acute medical illness that could interfere with study participation, including significant pulmonary disease
  • 8. Pregnancy or breastfeeding
  • 9. Any contraindications to the use of nitrous oxide (e.g., pneumothorax, middle ear occlusion, elevated intracranial pressure, chronic cobalamin or folate deficiency unless treated with folic acid or vitamin B12).

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Chicago,

Peter Nagele, MD, MSc, PRINCIPAL_INVESTIGATOR, University of Chicago, Department of Anesthesia and Critical Care

Paul Myles, MD, PRINCIPAL_INVESTIGATOR, The Alfred Hospital, Department of Anesthesiology and Perioperative Medicine

Study Record Dates

2025-12-01